Special Professor, juntendo, Japan
Dr. Toshifumi Ohkusa is a highly regarded expert in gastroenterology and microbiota research, with a distinguished career spanning over four decades. He is currently a Special Professor at the Department of Microbiota Research at Juntendo University Graduate School of Medicine. Dr. Ohkusa has made significant contributions to the field of gastroenterology, particularly in understanding ulcerative colitis and intestinal microflora. 🌟👨⚕️
Publication profile
Scopus
Education
Dr. Ohkusa completed his medical degree (M.D.) from Tokyo Medical and Dental University in 1978. He pursued a Ph.D. from the same institution, where his groundbreaking research on ulcerative colitis in hamsters through dextran sulfate sodium and changes in intestinal microflora earned him a doctorate in 1986. 🎓📚
Experience
With an impressive academic journey, Dr. Ohkusa served as a Research Associate and Instructor at Tokyo Medical and Dental University from 1986 to 2001. He later joined Juntendo University, where he advanced from Assistant Professor to Associate Professor in the Department of Gastroenterology. Between 2008 and 2017, he held the prestigious position of Professor at The Jikei University Kashiwa Hospital. Currently, he leads microbiota research at Juntendo University. 💼🔬
Research Focus
Dr. Ohkusa’s research focuses on gastroenterology, particularly the mechanisms of ulcerative colitis and the role of intestinal microflora in gastrointestinal diseases. His work on microbiota research has significantly advanced the understanding of gastrointestinal health. 🔬🧫
Awards and Honors
Dr. Ohkusa has received numerous accolades for his groundbreaking work in gastroenterology and internal medicine, earning recognition from both Japanese and international medical societies. 🏆🌍
Publication Top Notes
Effect of probiotic bifidobacterium breve in improving cognitive function and preventing brain atrophy in older patients with suspected mild cognitive impairment: Results of a 24-week randomized, double-blind, placebo-controlled trial
Analysis of the NUDT15 gene and metabolites of azathioprine in Japanese patients with inflammatory bowel disease
Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis (BMC Gastroenterology, (2022), 22, 1, (390), 10.1186/s12876-022-02474-9)